drugset / Trial / NCT05744687
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer
Timeline
- Start
- 2023-04-24
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPH4336 | Unknown | 400 mg | Oral |
| Background | Letrozole | Other / unclassified | 2.5 mg | Oral |